On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies

Publisher： Bentham Science Publishers

E-ISSN： 2212-3954|5|3|239-252

ISSN： 1574-8898

Source： Recent Patents on CNS Drug Discovery, Vol.5, Iss.3, 2010-11, pp. : 239-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential of Xeloda® in Colorectal Cancer and Other Solid Tumors

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 27-32

Karger

Access to resources Recommend Favorite

Molecular Targeted Therapies for Solid Tumors: Management of Side Effects

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 129-138

Karger

Access to resources Recommend Favorite

Solid lipid nanoparticle-incorporated gel: the future treatment for skin infections?

By Kumar Abhinesh   Sawant Krutika K  

Nanomedicine, Vol. 8, Iss. 12, 2013-12 ,pp. : 1901-1903

Future Medicine

Access to resources Recommend Favorite

Circulating biomarkers of CNS tumors: an update

By Ilhan-Mutlu Aysegül   Wagner Ludwig   Preusser Matthias  

Biomarkers in Medicine, Vol. 7, Iss. 2, 2013-04 ,pp. : 267-285

Future Medicine

Access to resources Recommend Favorite

Treatment‐induced hearing loss and adult social outcomes in survivors of childhood CNS and non‐CNS solid tumors: Results from the St. Jude Lifetime Cohort Study

By  

CANCER, Vol. 121, Iss. 22, 2015-11 ,pp. : 4053-4061

John Wiley & Sons Inc

Access to resources Recommend Favorite